RecruitingNCT04978948

Study of STIM1 Membrane Expression

Study of STIM1 Membrane Expression During Autoimmune Diseases


Sponsor

University Hospital, Brest

Enrollment

670 participants

Start Date

May 11, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

The aim of this study is to determine the expression of STIM1 in the plasma membrane of lymphocytes from patients suffering from different autoimmune diseases in order to identify new pathologies of interest presenting an over-expression of STIM1PM. This would allow to initiate, following this study, research and development programs on the use of anti-STIM1 antibodies in these identified autoimmune diseases of interest.


Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with autoimmune diseases. The study is currently recruiting participants at 4 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(4)

CHRU de Brest - Service de rhumatologie

Brest, Brest, France

Centre Hospitalier des Pays de Morlaix

Morlaix, Brittany Region, France

Centre Hospitalier de Quimper

Quimper, Brittany Region, France

CHU de Martinique

Fort-de-France, Martinique, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04978948


Related Trials